latanoprost and Retinal-Detachment

Cystoid macular edema associated with latanoprost administration has been reported in patients after complicated cataract surgery with coexisting risk factors. We present the first case of preservative free latanoprost associated cystoid macular edema that occurred many months after uncomplicated cataract surgery.. A 65-year old Caucasian female presented in the Outpatients Clinic complaining of reduced vision and metamorphopsia in the right eye. She had undergone uneventful phacoemulsification 19 months ago in the right eye and was under treatment with preservative free latanoprost eye drops for the last 7 months for ocular hypertension. Her remaining medical and ocular history were otherwise unremarkable. Cystoid macular edema with serous retinal detachment was diagnosed in the right eye using optical coherence tomography and fluorescein angiography. Latanoprost was discontinued and brinzolamide and nepafenac eye drops were administered in the right eye. Two months later, cystoid macular edema completely resolved with restoration of visual acuity. Nepafenac eye drops were administered for another 2 months. Eight months after latanoprost cessation optical coherence demonstrated no sign of cystoid macular edema whereas a subtle epiretinal membrane was noted.. Cystoid macular edema may potentially occur in patients receiving preservative free latanoprost. More interestingly, in our case it was diagnosed in a patient with a long standing pseudophakia after uncomplicated phacoemulsification. No obvious risk factor for macular edema development was recognized. Prompt diagnosis and latanoprost discontinuation resulted in complete resolution of the cystoid macular edema and functional restoration of the eye.

Topics: Aged; Antihypertensive Agents; Female; Humans; Latanoprost; Macular Edema; Phacoemulsification; Prostaglandins F, Synthetic; Retinal Detachment

Topics: Acetazolamide; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Benzophenones; Bromobenzenes; Carbonic Anhydrase Inhibitors; Choroid; Choroid Diseases; Ciliary Body; Drug Therapy, Combination; Fluorescein Angiography; Fundus Oculi; Humans; Latanoprost; Male; Microphthalmos; Middle Aged; Retina; Retinal Detachment; Syndrome; Tomography, Optical Coherence; Uveal Diseases

To report a case series of three patients with bilateral uveal effusion syndrome (UES), treated conservatively with oral carbonic anhydrase inhibitors and topical prostaglandin analogues (PAs).. Three patients with bilateral UES were treated with the same initial therapy. Topical PA latanoprost 0.005% and acetazolamide 250 mg were administered in order to reduce intraocular pressure, improve uveoscleral outflow, and facilitate resolution of uveal effusion.. The chorioretinal detachment resolved within 3 months in two reported patients while the third one underwent surgery on his left eye. After clinical improvement, further oral therapy with acetazolamide was stopped, while topical prostaglandins were continued for at least the next 3 months. All patients were free from recurrence during the follow-up period.. Although the usually recommended UES therapy is partial or full-thickness sclerectomy, our case series showed apparent resolution of chorioretinal detachment in two patients on medical therapy alone. Conservative therapy may be the first step before the standard recommended surgical approach, but further studies are needed to verify the effectiveness of reported therapy.

Topics: Acetazolamide; Administration, Oral; Administration, Topical; Adult; Antihypertensive Agents; Carbonic Anhydrase Inhibitors; Choroid Diseases; Drug Therapy, Combination; Female; Humans; Intraocular Pressure; Latanoprost; Magnetic Resonance Imaging; Male; Middle Aged; Prostaglandins F, Synthetic; Retinal Detachment; Uveal Diseases

To report a case of central serous chorioretinopathy (CSC) as a possible complication of latanoprost treatment.. A 65-year-old woman presented with a 1-week history of blurred vision and metamorphopsia in her right eye. She was previously diagnosed with unilateral glaucoma, and treatment was initiated with topical latanoprost 0.005% for the right eye. The symptoms occurred 1 month after initiation of glaucoma treatment.. Visual acuity (VA) of the patient had reduced to 20/50 in right eye. Fluorescein angiography revealed a focal RPE leak near to the fovea with neurosensory detachment due to CSC, which was confirmed by optical coherence tomography. After cessation of the therapy, her clinical and morphological status improved spontaneously. The neurosensory detachment resolved almost completely and VA improved to 20/20 simultaneously.. The authors report the first case of CSC associated with latonoprost therapy. This case demonstrates that topical latanoprost may lead to the development of CSC.

Topics: Aged; Antihypertensive Agents; Central Serous Chorioretinopathy; Female; Fluorescein Angiography; Glaucoma; Humans; Latanoprost; Prostaglandins F, Synthetic; Remission, Spontaneous; Retinal Detachment; Tomography, Optical Coherence; Treatment Outcome; Visual Acuity

A 67-year-old woman referred to our clinic complaining of decrease in vision and metamorphopsia for 1 month after initiating latanoprost therapy. Fundus examination and optical coherence tomography (OCT) revealed serous detachment in the macula. The macular thickness measured by OCT was 532 microm. Latanoprost was discontinued. At follow-up, a progressive decrease in macular thickness and increase in visual acuity was observed. Four months later, serous detachment was completely resolved, and macular thickness measured by OCT was 186 mum. Latanoprost may lead a serous retinal detachment in the posterior pole. Clinicians should keep in mind that decreased visual acuity in patients using latanoprost might be related with this complication.

Topics: Aged; Antihypertensive Agents; Female; Fluorescein Angiography; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Macula Lutea; Prostaglandins F, Synthetic; Retinal Detachment; Serum; Tomography, Optical Coherence; Visual Acuity

Topics: Antihypertensive Agents; Blood-Retinal Barrier; Brimonidine Tartrate; Diagnosis, Differential; Drug Therapy, Combination; Fluorescein Angiography; Glaucoma; Humans; Latanoprost; Male; Middle Aged; Myopia; Prostaglandins F, Synthetic; Quinoxalines; Retinal Detachment; Visual Acuity

To describe the occurrence of cystoid macular edema in a pseudophakic vitrectomized patient following use of latanoprost (0.005%).. A 58-year-old patient underwent routine cataract surgery with posterior chamber lens implantation complicated by rhegmatogenous retinal detachment three months later. A pars plana vitrectomy was performed with silicone oil endotamponade which was removed six months later. Five months after oil removal, the patient presented with secondary open-angle glaucoma treated with latanoprost 0.005% eye drops once daily.. Two weeks after initiation of latanoprost treatment, visual acuity dropped from 0.8 to 0.3 due to cystoid macular edema confirmed by fluorescein angiography. After discontinuing latanoprost therapy and with topical corticosteroid treatment, cystoid macular edema slowly resolved, and within 6 months, visual acuity improved to 0.8.. Despite its marked ocular hypotensive effect, latanoprost should be carefully used in patients after uncomplicated cataract surgery if the vitreous body was removed by pars piana vitrectomy.

Topics: Antihypertensive Agents; Drainage; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Lens Implantation, Intraocular; Macular Edema; Middle Aged; Phacoemulsification; Prostaglandins F, Synthetic; Pseudophakia; Retinal Detachment; Silicone Oils; Vitrectomy

Topics: Aged; Antihypertensive Agents; Cataract Extraction; Choroid Diseases; Glaucoma, Open-Angle; Humans; Latanoprost; Male; Prostaglandins F, Synthetic; Retinal Detachment

Topics: Aged; Anti-Inflammatory Agents; Antihypertensive Agents; Choroid Diseases; Glaucoma, Open-Angle; Humans; Latanoprost; Male; Phacoemulsification; Prednisolone; Prostaglandins F, Synthetic; Retinal Detachment; Treatment Outcome